

AMENDMENTS TO THE CLAIMS:


This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1. (Currently Amended) Combination product comprising:

- (i) at least one nucleic acid containing a sequence encoding a polypeptide of interest, and
- (ii) at least one phospholipid of interest, for use which is simultaneous, consecutive or spread out over time, characterized in that said polypeptide and phospholipid of interest have cytotoxic activity and the said phospholipid of interest has a general formula:

(A)



in which:

R₁ is either a linear or branched carbon-based chain comprising from 6 to 30 carbon atoms

R₂, R₃ and R₄ are either hydrogen atoms or alkyl residues containing from 1 to 5 carbon atoms,

m is a positive integer ranging from 1 to 6 and

n is a positive integer ranging from 0 to 1.

Claim 2. (Canceled)

Claim 3. (Previously Presented) The combination product of Claim 1, wherein R_1 is a linear or branched carbon-based chain comprising from 12 to 22 carbon atoms.

Claim 4. (Original) The combination product of Claim 3, wherein R_1 is a linear or branched carbon-based chain comprising 16 carbon atoms.

Claim 5. (Previously Presented) The combination product of Claim 1, wherein R_1 is an alkyl, alkenyl, alkynyl or aralkyl residue.

Claim 6. (Canceled)

Claim 7. (Previously Presented) The combination product of Claim 1, wherein R_1 is an alkyl residue comprising 16 carbon atoms.

Claim 8. (Original) The combination product of Claim 1, wherein said polypeptide of interest is selected from cytokines, proteins encoded by a suicide gene, anti-angiogenic protein factors, polypeptides having chemoattractant activity and polypeptides having activity for activating cellular apoptosis.

Claim 9. (Original) The combination product of Claim 8, wherein said polypeptide of interest is a cytokine chosen from the group consisting of alpha, beta and gamma interferon, interleukins, tumour necrosis factors and colony stimulating factors.

Claim 10. (Original) The combination product of Claim 9, wherein said cytokine is

interleukin-2 (IL-2) or gamma interferon (γ -IFN).

Claim 11. (Original) The combination product of Claim 1, that also comprises:

- (iii) a substance which associates with nucleic acids and/or
- (iv) a substance which associates with the phospholipid of interest.

Claim 12. (Original) The combination product of Claim 11, wherein said substance (iii) is a cationic lipid or a cationic polymer.

Claim 13. (Original) The combination product of Claim 11, wherein said substance (iv) is a lipid capable of integrating into a liposome.

Claim 14. (Original) The combination product of Claim 11, also containing an adjuvant (v) selected from the group consisting of neutral, zwitterionic and negatively charged lipids.

Claim 15. (Original) The combination product of Claim 14, wherein said adjuvant (v) is selected from the group consisting of cholesterol, dioleoylphosphatidylethanolamine (DOPE) and derivatives thereof.

Claim 16. (Original) The combination product of Claim 11, wherein said nucleic acid (i), said substance (iii), said phospholipid (ii) and, optionally, said adjuvant (v) form a complex.

Claim 17. (Original) The combination product of Claim 16, wherein the ratio between

the number of positive charges and the number of negative charges of the elements forming said complex ranges between 0.05 and 20.

Claim 18. (Original) The combination product of Claim 16, wherein said complex has a diameter of between 20 and 800 nm.

Claim 19. (Previously Presented) The combination product of Claim 1, 11 or 16, wherein said nucleic acid (i) is a recombinant vector of plasmid or viral origin.

Claim 20. (Previously Presented) The combination product of Claim 1, 11 or 16, wherein it is formulated in a vehicle which is acceptable from a pharmaceutical point of view.

Claim 21. (Original) Complex comprising at least one nucleic acid (i) containing a sequence encoding a polypeptide of interest, at least one phospholipid (ii) of interest, a substance (iii) which associates with nucleic acids and, optionally, an adjuvant (v), wherein said phospholipid of interest (ii) is as described in any of Claims 1 to 7.

Claim 22. (Withdrawn) A method for treating the human or animal body comprising administering an effective amount of the combination product of claim 1 to a human or animal in need of such treatment.

Claim 23. (Withdrawn) The method according to Claim 22, wherein the treatment is an antitumour and/or antimetastatic treatment.

Claim 24. (Withdrawn) The method according to Claim 22, wherein said phospholipid of interest (ii) is administered simultaneously with the nucleic acid (i).

Claim 25. (Withdrawn) The method according to claim 22, wherein said combination product or said complex is administered intratumorally or peritumorally.

Claim 26. (Withdrawn) The method according to Claim 21, for simultaneously introducing a nucleic acid sequence (i) and a phospholipid (ii) into a cell.